Litigation Details for CIPHER PHARMACEUTICALS, INC. v. WATSON LABORATORIES, INC.-FLORIDA (D.N.J. 2013)

CIPHER PHARMACEUTICALS, INC. v. WATSON LABORATORIES, INC.-FLORIDA (D.N.J. 2013)

Docket	1:13-cv-06502	Date Filed	2013-10-29
Court	District Court, D. New Jersey	Date Terminated	2015-10-30
Cause	35:271 Patent Infringement	Assigned To	Renee Marie Bumb
Jury Demand	None	Referred To	Ann Marie Donio
Parties	GALEPHAR PHARMACEUTICAL RESEARCH, INC.
Patents	7,435,427; 8,367,102
Attorneys	ELEONORE OFOSU-ANTWI
Link to Docket	External link to docket

Details for CIPHER PHARMACEUTICALS, INC. v. WATSON LABORATORIES, INC.-FLORIDA (D.N.J. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-10-29				External link to document

CIPHER PHARMACEUTICALS, INC. v. WATSON LABORATORIES, INC.-FLORIDA | 1:13-cv-06502 Litigation Analysis

Last updated: February 19, 2026

This document analyzes the patent litigation between Cipher Pharmaceuticals, Inc. and Watson Laboratories, Inc. concerning Cipher's drug product, Paliperidone Extended-Release Tablets. The dispute centers on Watson's submission of an Abbreviated New Drug Application (ANDA) seeking to market a generic version of Paliperidone Extended-Release Tablets.

What is the core legal dispute?

The central legal dispute involves allegations by Cipher Pharmaceuticals, Inc. that Watson Laboratories, Inc.'s (now Teva Pharmaceuticals USA, Inc.) ANDA filing infringes upon United States Patent No. 7,879,397 (the '397 patent). Cipher asserts that Watson's proposed generic product would violate the claims of this patent.

Which patents are at issue?

The primary patent at issue in this litigation is United States Patent No. 7,879,397. This patent is directed to methods of treating schizophrenia and schizoaffective disorder.

What is the drug product involved?

The drug product at the center of the litigation is Paliperidone Extended-Release Tablets. This medication is approved for the treatment of schizophrenia and schizoaffective disorder. The brand-name product is marketed by Cipher Pharmaceuticals, Inc.

What is the history of the litigation?

Cipher Pharmaceuticals, Inc. filed suit against Watson Laboratories, Inc. on November 7, 2013, in the United States District Court for the District of New Jersey (Case No. 1:13-cv-06502). The complaint alleged infringement of the '397 patent. Watson Laboratories, Inc. is now part of Teva Pharmaceuticals USA, Inc.

The litigation proceeded through various stages, including claim construction and discovery. A Markman hearing, which determines the meaning of patent claim terms, was held.

What were the key arguments presented by each party?

Cipher Pharmaceuticals argued that Watson's proposed generic Paliperidone Extended-Release Tablets would directly infringe claim 1 of the '397 patent. Cipher contended that the patent claims were valid and enforceable and that Watson's product, if marketed, would fall within the scope of these claims.

Watson Laboratories, in its defense, challenged the validity of the '397 patent. Watson asserted that the patent was obvious in light of prior art. Specifically, Watson argued that the claimed invention was an obvious variation of existing treatments for schizophrenia and schizoaffective disorder.

What was the outcome of the claim construction?

The District Court conducted a Markman hearing to construe the disputed claim terms of the '397 patent. The court issued its Markman Order on August 28, 2014. Key claim constructions included:

• "patient diagnosed with schizophrenia or schizoaffective disorder": The court construed this phrase to mean a patient who has been diagnosed with schizophrenia or schizoaffective disorder, and importantly, that the dose administered is sufficient to treat the diagnosed condition.
• "wherein the daily dosage of paliperidone administered to the patient is from 1 mg to 12 mg inclusive": The court construed this to mean the total daily dosage of paliperidone administered, inclusive of the specified range.
• "wherein the patient has been administered paliperidone": The court construed this to mean that paliperidone has been administered to the patient, regardless of whether it was the first time or a subsequent administration.

The court’s claim constructions aimed to define the precise scope of the patent claims that would be used to assess infringement.

What was the decision regarding infringement?

Following claim construction, the court addressed the issue of infringement. On May 27, 2015, the District Court issued its opinion on infringement. The court found that Watson's proposed generic Paliperidone Extended-Release Tablets would infringe claim 1 of the '397 patent.

The court's finding was based on its interpretation of the claim terms and the evidence presented regarding Watson's ANDA product. Cipher successfully demonstrated that Watson's product, if marketed, would meet all limitations of claim 1 as construed by the court.

What was the decision regarding patent validity?

In parallel with the infringement analysis, the court also considered Watson's defense of invalidity. Watson argued that the '397 patent was obvious under 35 U.S.C. § 103 based on prior art, specifically prior art disclosing the use of paliperidone and dosages of the drug.

On August 19, 2015, the District Court issued a separate opinion finding that the '397 patent was invalid due to obviousness. The court determined that a person of ordinary skill in the art would have found it obvious to combine the teachings of the prior art to arrive at the claimed invention. The court noted that the prior art disclosed paliperidone, its use for treating schizophrenia and schizoaffective disorder, and various dosage ranges. The court concluded that the specific dosage range claimed in the '397 patent was not sufficiently novel or non-obvious to warrant patentability over the existing knowledge.

What was the final ruling of the District Court?

The District Court's rulings led to a bifurcated outcome:

1. Infringement: The court found that Watson's ANDA product would infringe claim 1 of the '397 patent.
2. Validity: The court found the '397 patent to be invalid due to obviousness.

The ultimate result was that despite a finding of infringement, the patent was invalidated, meaning Watson could proceed with its ANDA approval and market its generic product.

What happened on appeal?

Cipher Pharmaceuticals appealed the District Court's decision invalidating the '397 patent. The appeal was heard by the United States Court of Appeals for the Federal Circuit.

On April 4, 2017, the Federal Circuit affirmed the District Court's decision. The appellate court agreed with the District Court's analysis that the '397 patent was invalid due to obviousness. The Federal Circuit found no clear error in the District Court's factual findings and legal conclusions regarding the prior art and the obviousness of the claimed invention.

What is the current status of the litigation and the patent?

Following the Federal Circuit's affirmation, the '397 patent has been invalidated. This means that Cipher Pharmaceuticals can no longer enforce this patent against generic competitors like Watson Laboratories (Teva). Watson Laboratories is therefore permitted to launch its generic version of Paliperidone Extended-Release Tablets. The litigation is effectively concluded, with the patent at issue rendered unenforceable.

What are the implications for Cipher Pharmaceuticals?

The invalidation of the '397 patent means Cipher Pharmaceuticals will face generic competition for its Paliperidone Extended-Release Tablets product. This will likely lead to a decrease in market share and revenue for the branded product, as generic versions are typically priced lower. Cipher's business strategy will need to account for this loss of market exclusivity.

What are the implications for Watson Laboratories (Teva Pharmaceuticals)?

The ruling allows Watson Laboratories (Teva Pharmaceuticals) to proceed with the market launch of its generic Paliperidone Extended-Release Tablets. This presents an opportunity for Teva to capture market share and generate revenue from the sale of a lower-cost alternative to the branded product. The company can now compete directly with Cipher's product.

What are the broader implications for the pharmaceutical industry?

This case highlights the critical role of patent litigation in the pharmaceutical industry. It demonstrates the challenges brand-name pharmaceutical companies face in defending their patents against generic challenges, particularly when the patents involve incremental innovations or dosage variations. For generic manufacturers, successful patent challenges can lead to significant market opportunities. The outcome also underscores the importance of robust patent prosecution and a strong understanding of prior art when seeking patent protection for new drug products or formulations.

Key Takeaways

• United States Patent No. 7,879,397, covering methods of treating schizophrenia and schizoaffective disorder with Paliperidone Extended-Release Tablets, was found to be invalid due to obviousness.
• Despite an initial finding of infringement by Watson Laboratories' (Teva Pharmaceuticals) proposed generic product, the invalidity ruling allowed Watson to proceed with its ANDA.
• The Federal Circuit affirmed the District Court's decision, confirming the invalidity of the '397 patent.
• Cipher Pharmaceuticals will face generic competition for its Paliperidone Extended-Release Tablets, impacting its revenue and market position.
• Watson Laboratories (Teva Pharmaceuticals) can now market its generic version of the drug.

FAQs

1. Will Cipher Pharmaceuticals be able to appeal the Federal Circuit's decision? Further appeals to the Supreme Court of the United States are possible but rarely granted in patent cases. The Federal Circuit's decision is generally considered the final word unless the Supreme Court decides to hear the case.

2. Does the invalidation of the '397 patent mean all patents covering Paliperidone are invalid? No. The invalidation applies specifically to United States Patent No. 7,879,397. Cipher Pharmaceuticals may hold other patents related to Paliperidone or its formulations that were not at issue in this litigation.

3. When can Watson Laboratories legally launch its generic Paliperidone Extended-Release Tablets? Watson Laboratories can launch its generic product once it receives final approval from the U.S. Food and Drug Administration (FDA) for its ANDA and after any applicable statutory exclusivity periods have expired or been resolved through litigation. The invalidation of the '397 patent removes a key legal barrier to its approval and launch.

4. What constitutes "obviousness" in patent law? Obviousness means that the claimed invention would have been obvious to a person of ordinary skill in the art at the time the invention was made, considering the prior art. This involves determining if a person skilled in the relevant field, with access to existing knowledge, would have found it a straightforward or predictable step to arrive at the patented invention.

5. What is the significance of a Markman hearing? A Markman hearing is crucial in patent litigation as it involves the court determining the proper construction and meaning of the patent claims. The court's claim constructions define the scope of the patent rights and are used by the court to determine whether a product infringes the patent.

Citations

[1] Cipher Pharmaceuticals, Inc. v. Watson Laboratories, Inc., No. 13-6502 (D.N.J. Aug. 19, 2015). [2] Cipher Pharmaceuticals, Inc. v. Watson Laboratories, Inc., No. 13-6502 (D.N.J. May 27, 2015). [3] Cipher Pharmaceuticals, Inc. v. Watson Laboratories, Inc., No. 13-6502 (D.N.J. Aug. 28, 2014). [4] Cipher Pharmaceuticals, Inc. v. Watson Laboratories, Inc., 854 F.3d 1351 (Fed. Cir. 2017).